Atrial Fibrillation – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Atrial Fibrillation – Drugs In Development, 2024 report and make more profitable business decisions.
Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.
The Atrial Fibrillation drugs in development market research report provide comprehensive information on the therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Atrial Fibrillation | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 32 molecules, with 31 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Atrial Fibrillation therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Atrial Fibrillation pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Atrial Fibrillation treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acesion Pharma ApsAnaBios Corp
Anthos Therapeutics Inc
AOP Health
ARCA biopharma Inc
Bristol-Myers Squibb Co
Chaperone Pharma BV
Correvio Pharma Corp
Daiichi Sankyo Co Ltd
FB HRS LLC
Fuso Pharmaceutical Industries Ltd
G3 Pharmaceuticals Inc
Hanmi Pharmaceuticals Co Ltd
HUYA Bioscience International LLC
Hyloris Pharmaceuticals SA
InCarda Therapeutics Inc
Inomagen Therapeutics Inc
Merck & Co Inc
Merz Pharma GmbH & Co KgaA
Milestone Pharmaceuticals Inc
Nissan Chemical Corp
Rithim Biologics Inc
The Geneva Biotech Center SA
Thryv Therapeutics Inc
Toa Eiyo Ltd
Vanderbilt University
Verseon Corp
Vivasc Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Atrial Fibrillation reports